Underwriting AgreementUnderwriting Agreement • February 26th, 2015 • Lilly Eli & Co • Pharmaceutical preparations • New York
Eli Lilly and Company, an Indiana corporation (the “Company”), proposes to issue and sell to the several Underwriters listed in Schedule 1 hereto (the “Underwriters”), for whom you are acting as representatives (the “Representatives”), $600,000,000 principal amount of its 1.250% Notes due 2018 (the “2018 Notes”), $800,000,000 principal amount of its 2.750% Notes due 2025 (the “2025 Notes”) and $800,000,000 principal amount of its 3.700% Notes due 2045 (the “2045 Notes”), in each case having the terms set forth in Schedule 2 hereto (such 2018 Notes, 2025 Notes and 2045 Notes collectively, the “Securities”). The Securities will be issued pursuant to an Indenture dated as of February 1, 1991 (as may be supplemented from time to time, the “Indenture”) between the Company and Deutsche Bank Trust Company Americas, a New York banking corporation (as successor to Citibank, N.A., the original trustee), as trustee (the “Trustee”).
